Public Health


Health Policy 101 is a comprehensive guide covering fundamental aspects of U.S. health policy and programs, including Medicare, Medicaid, the Affordable Care Act, employer-sponsored insurance, the uninsured population, health care costs and affordability, women's health issues, and health care politics. The Public Health chapter examines how public health is governed and delivered in the United States. It includes explanations of key public health frameworks, services, capabilities and characteristics, how the public health system works in state, local and territorial governments, and public health funding, workforce, and communication challenges in an era of declining trust.

View the Chapter →


Filter

111 - 120 of 259 Results

  • How HHS, FDA, and CDC Can Influence U.S. Vaccine Policy

    Policy Watch

    This policy brief highlights areas in which HHS, FDA, and CDC have authority to shape U.S. vaccine policy with a specific focus on vaccine approvals and recommendations for the public. Ultimately, while there are limits, federal officials have significant authority to influence and alter vaccine policy, which could affect vaccine availability, views about vaccines, and vaccine use in the U.S. However, this does not include imposing mandates on or changing local vaccination requirements, as those authorities rest with state and local governments.

  • How Does the Federal Government Monitor Vaccine Safety?

    Issue Brief

    This issue brief gives an overview of the main systems used by the federal government to track vaccine safety and adverse events following vaccinations. The brief reviews the history of federal vaccine safety systems, describes the key systems and their strengths and limitations, and also discusses how vaccine safety issues have become the subject of more scrutiny under the Trump administration.

  • Federal Vaccine Advisory Committees: Roles and Current Issues

    Issue Brief

    This brief describes four key federal vaccine advisory committees and discusses policy issues and questions they currently face. The four committees are the Vaccines and Related Biological Products Advisory Committee (VRBPAC) at the Food and Drug Administration (FDA); the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC); the National Vaccine Advisory Committee (NVAC) at the Department of Health and Human Services (HHS); and the Advisory Commission on Childhood Vaccines (ACCV) at HHS.

  • How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?

    Issue Brief

    This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.

  • What’s Next for Health Policy After the Election?

    Event Date:
    Event

    On Tuesday, November 15, two experts joined series moderator Larry Levitt in a 45-minute discussion looking at what’s ahead for health policy on the Hill, in the Administration, and in the states after the election.

  • How Many People Might Lose Medicaid When States Unwind Continuous Enrollment?

    Issue Brief

    Between 8 and 24 million people across the U.S. could be disenrolled from Medicaid during the unwinding of the program’s continuous enrollment provision. KFF's new analysis offers three illustrative scenarios for how state-level Medicaid enrollment could decline between March 2023 and May 2024, ranging from 8 percent to 28 percent of total enrollees.